Moreover, the use of potential pharmaceutical compounds like MG132, a PSMA2 inhibitor known to exert anti-viral activity against HSV-1, trematinib which increases HLA-A expression via IFN gamma/STAT1 signaling and STAT3 activation and other tyrosine kinase inhibitors, need to be employed to identify novel anti-viral compounds against ZIKV infection [118,119,120,121]. This evidence concerns the gene STAT3 and Zika virus infectious disease.